Bausch Health Companies Inc. (BHC)

NYSE: BHC · Real-Time Price · USD
4.700
0.00 (0.00%)
May 8, 2025, 4:00 PM EDT - Market closed
0.00%
Market Cap 1.74B
Revenue (ttm) 9.73B
Net Income (ttm) -40.00M
Shares Out 369.55M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE 1.18
Dividend n/a
Ex-Dividend Date n/a
Volume 1,935,549
Open 4.770
Previous Close 4.700
Day's Range 4.705 - 4.850
52-Week Range 3.960 - 9.850
Beta 0.34
Analysts Hold
Price Target 7.20 (+53.19%)
Earnings Date Apr 30, 2025

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,700
Stock Exchange NYSE
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $7.2, which is an increase of 53.19% from the latest price.

Price Target
$7.2
(53.19% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approv...

1 day ago - Business Wire

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...

2 days ago - Accesswire

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Confere...

8 days ago - Seeking Alpha

Bausch Health Announces First Quarter 2025 Results

First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies...

8 days ago - Accesswire

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)...

9 days ago - Accesswire

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health.

16 days ago - WSJ

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.

16 days ago - Reuters

Bausch Health Announces Filing of Supplement to Proxy Statement

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 ...

16 days ago - Accesswire

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...

17 days ago - Business Wire

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today...

21 days ago - Accesswire

Bausch Health Announces Adoption of Shareholder Rights Plan

LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approve...

24 days ago - Accesswire

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausc...

4 weeks ago - Accesswire

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Ca...

4 weeks ago - Accesswire

Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity

One-eighth of the global population and one-fifth of U.S. adults suffer from mental health conditions, highlighting an urgent need for better psychiatric care. Bausch Health's Aplenzin shows promise f...

4 weeks ago - Seeking Alpha

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagno...

5 weeks ago - Accesswire

Bausch + Lomb recalls some of its implantable eye lenses

Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.

6 weeks ago - Reuters

Bausch + Lomb Recalls EnVista Intraocular Lenses

The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.

6 weeks ago - Market Watch

Bausch Health to Announce First Quarter Results on April 30

LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Hea...

6 weeks ago - Accesswire

Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary re...

6 weeks ago - Business Wire

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.

Other symbols: CHWY
6 weeks ago - Benzinga

Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes

LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering ...

6 weeks ago - Accesswire

Bausch Health Announces Conditional Redemption of Senior Notes

LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of rede...

6 weeks ago - Accesswire

Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities

Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bau...

7 weeks ago - Accesswire

Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes

LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of ...

7 weeks ago - Accesswire

Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan

LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver bett...

7 weeks ago - Accesswire